Clinical trials evaluating reproxalap—an innovative small-molecule modulator designed to inhibit RASP (reactive aldehyde species)—have demonstrated rapid reductions in ocular inflammation and symptom scores in various studies. However, discrepancies across specific clinical endpoints in trials led regulatory authorities to request additional interpretive clarity and evidence regarding consistent signs and symptoms relief before granting final market clearance.